The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

As HIV cases continue to rise in the Philippines, especially among the youth, a new global development may offer hope in ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The proposed cuts have caused concerns among some Senate Republicans, including Utah Sen. John Curtis, who may consider ...

French health officials received dozens of reports of syringe pricks at a public festival, sparking fear about HIV and ...

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

The future of the global HIV response risks being undermined by shrinking funding and wavering political will, health leaders have warned as the International AIDS Society (IAS) Conference on HIV ...

When it comes to a clinical study to evaluate the therapeutic effect of Shivagutika treatment in patients with HIV, it was ...